Drug Trial Radar · NCT04557449
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
430
Planned (sponsor's estimate)
Start
Sep 23, 2020
Primary completion
Oct 7, 2029
Study completion Oct 7, 2029
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy. Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort. Part 2 includes dose expansion cohorts evaluating PF-07220060 in combination with endocrine therapy or enzalutamide. The Giredestrant Combination Cohort will evaluate PF-07220060 in combination with giredestrant. In Part 1A, single escalating doses of PF-07220060 alone will be administered to determine the maximum tolerated dose (MTD) and select the recommended dose for expansion. In Part 1B and Part 1C, PF-07220060 will be administered in combination with 1 of 2 endocrine therapies (letrozole and fulvestrant, respectively). In Part 1D, food effect assessment of PF-07220060 at the RP2D dose level from Part 1A will be conducted. In Part 1E, the effect of PF-07220060 on the PK of midazolam will be evaluated (DDI). In Part 1F, escalating doses of PF-07220060 will be administered in combination with enzalutamide. In Part 1G, PF-07220060 will be administered in combination with tamoxifen to determine the RDE. Part 2A is an expansion cohort for PF-07220060 in combination with fulvestrant and will explore more than one dose of PF-07220060. Part 2B and Part 2C are expansion cohorts for PF-07220060 in combination with letrozole and fulvestrant, respectively. Part 2E is an expansion cohort to evaluate PF-07220060 Monotherapy versus PF-07220060 plus fulvestrant combination therapy. Part 2F is an expansion cohort for PF-07220060 in combination with tamoxifen. The Giredestrant Combination Cohort Group A will determine the tolerable dose of PF-07220060 in combination with giredestrant. In Group B, additional participants will be enrolled at the tolerable dose to further assess safety and PK. The China and Japan monotherapy cohorts will evaluate safety, tolerability, and PK of PF-07220060 as single agent in Chinese and Japanese participants, respectively.
Conditions
- Liposarcoma
- Prostate Cancer
- Advanced Breast Cancer
- NSCLC (Non-small Cell Lung Cancer)
- Colorectal Cancer
Interventions
PF-07220060Drug
CDK4 inhibitor
LetrozoleCombination product
Endocrine Therapy
FulvestrantCombination product
Endocrine Therapy
MidazolamOther
Benzodiazepine
EnzalutamideCombination product
Androgen Receptor inhibitor
GiredestrantCombination product
Endocrine Therapy
TamoxifenCombination product
Endocrine Therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicities in the Dose Escalation or De-escalation PortionTime frame: At the end of Cycle 1 (each cycle is 28 days)
- Incidence of clinically significant AEsTime frame: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
- Incidence of clinically significant laboratory assessmentsTime frame: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
- Incidence of clinically significant abnormal vital and ECG parametersTime frame: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
- Maximal Plasma Concentration (Cmax) of PF-07220060 given with and without foodTime frame: Cycle 1 (each cycle is 28 days)
- Time to Maximum Plasma Concentration (Tmax) of PF-07220060 given with and without foodTime frame: Cycle 1 (each cycle is 28 days)
- Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Time Point (AUClast) of PF-07220060 given with and without foodTime frame: Cycle 1 (each cycle is 28 days)
- Maximal Plasma Concentration (Cmax) of Midazolam with and without PF-07220060Time frame: Cycle 1 (each cycle is 28 days)
- Time to Maximum Plasma Concentration (Tmax) of Midazolam with and without PF-07220060Time frame: Cycle 1 (each cycle is 28 days)
- Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Timepoint (AUClast) of Midazolam with and without PF-07220060Time frame: Cycle 1 (each cycle is 28 days)
- Steady State Maximal Concentration (Cmax,ss) of PF-07220060Time frame: Cycle 1 (each cycle is 28 days)
- Steady State Time to Maximum Plasma Concentration (Tmax,ss) of PF-07220060Time frame: Cycle 1 (each cycle is 28 days)
- Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCτ,ss) of PF-07220060Time frame: Cycle 1 (each cycle is 28 days)
- Steady State Minimum Plasma Concentration (Cmin,ss) of PF-07220060Time frame: Cycle 1 (each cycle is 28 days)
- Steady State Maximal Concentration (Cmax,ss) of GiredestrantTime frame: Cycle 1 (each cycle is 28 days)
- Steady State Time to Maximum Plasma Concentration (Tmax,ss) of GiredestrantTime frame: Cycle 1 (each cycle is 28 days)
- Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCτ,ss) of GiredestrantTime frame: Cycle 1 (each cycle is 28 days)
- Steady State Minimum Plasma Concentration (Cmin,ss) of GiredestrantTime frame: Cycle 1 (each cycle is 28 days)
Locations
39 sites in 8 countries. Site status is shown where the registry gives one.
Ellison Institute
Los Angeles, California · Recruiting
Smilow Cancer Hospital - Yale New Haven Health
New Haven, Connecticut · Recruiting
Yale-New Haven Hospital-Yale Cancer Center
New Haven, Connecticut · Recruiting
Smilow Cancer Hospital Phase 1 Unit
New Haven, Connecticut · Recruiting
Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP
New Haven, Connecticut · Recruiting
Smilow Cancer Hospital - Trumbull
Trumbull, Connecticut · Recruiting
Brigham & Women's Hospital
Boston, Massachusetts · Active not recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Active not recruiting
Dana Farber Cancer Institute- Chestnut Hill
Newton, Massachusetts · Active not recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Sarah Cannon Research Institute - Pharmacy
Nashville, Tennessee · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
The University of Texas, MD Anderson Cancer Center - West Houston
Houston, Texas · Recruiting
Fundación Respirar
Buenos Aires, Argentina · Active not recruiting
Clínica Universitaria Reina Fabiola
Córdoba, Argentina · Active not recruiting
Fundación CORI para la Investigación y Prevención del Cáncer
La Rioja, Argentina · Active not recruiting
Hospital Británico de Buenos Aires
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Active not recruiting
Fundación Cenit Para La Investigación En Neurociencias
CABA, Ciudad Autã³noma de Buenos Aires, Argentina · Active not recruiting
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, China · Active not recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Active not recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Active not recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China · Active not recruiting
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Active not recruiting
Vseobecna fakultni nemocnice v Praze
Prague, Czechia · Active not recruiting
National Cancer Center Hospital East
Kashiwa, Chiba, Japan · Active not recruiting
Oaxaca Site Management Organization
Oaxaca City, Mexico · Active not recruiting
COI Centro Oncologico Internacional S.A.P.I. de C.V.
Mexico City, Mexico City, Mexico · Active not recruiting
Hospital MAC Periferico Sur
Mexico City, Mexico City, Mexico · Active not recruiting
INCAN
Mexico City, Mexico City, Mexico · Active not recruiting
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Monterrey, Nuevo León, Mexico · Active not recruiting
Hospital Reforma
Oaxaca City, Oaxaca, Mexico · Active not recruiting
Onkologicky ustav sv. Alzbety, s.r.o., Interna klinika VSZaSP a OUSA
Bratislava, Slovakia · Active not recruiting
Narodny onkologicky ustav
Bratislava, Slovakia · Active not recruiting
Fakultna nemocnica s poliklinikou Nove Zamky
Nové Zámky, Slovakia · Active not recruiting
Sarah Cannon Research Institute UK
London, United Kingdom · Active not recruiting
The Christie Hospital NHS Foundation Trust
Manchester, United Kingdom · Active not recruiting
Cancer Research UK Edinburgh Centre
Edinburgh, Edinburgh, CITY of, United Kingdom · Active not recruiting
St Bartholomew's Hospital
London, London, CITY of, United Kingdom · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.